Board of Directors

Company
Board of Directors

Board of Directors

Danièle GUYOT-CAPARROS

Danièle Guyot-Caparros is a chartered accountant and graduate from the Ecole Supérieure de Commerce in Nancy.

Danièle Guyot-Caparros is graduated from the Ecole Supérieure de Commerce of Nancy in finance and accounting. Following international missions in Audit, she joined Rhone Poulenc (now Sanofi) where she has held different positions with an increasing scope of responsibilities in finance on a European level and in business planning and performance monitoring on a worldwide level. Danièle Guyot-Caparros has been working as a consultant specialized in life sciences and healthcare areas for 5 years.

Danièle Guyot-Caparros has been a director of Onxeo since 26 June 2013 and Chairperson of the Board of Directors since 22 May 2019.. Her mandate will expire at the annual shareholders’ general meeting of 2019.

Last updated on 09/20/2019

Danièle GUYOT-CAPARROS

CHAIRPERSON

JUDITH GRECIET

Doctor of Pharmacy with a master’s degree in management and pharmaceutical marketing, Judith Greciet spent some fifteen years working her way up through subsidiaries of international pharmaceutical companies. She has held major managerial positions with increasing operational and strategic responsibilities from leading sales teams, heading marketing and strategy departments (Pharmacia, Zeneca, LFB, Wyeth France (now Pfizer)) until she finally became President of the French subsidiary of the Japanese laboratory Eisai in June 2007. Throughout her career, Judith Greciet has cultivated a keen awareness of the marketing and business environment of drugs, in France in particular and more broadly in Europe, as well as confronting market access issues, particularly in the areas of oncology and immunology with innovative products such as Enbrel (rheumatology).

Appointed Chief Executive Officer of Onxeo in 2011 (BioAlliance Pharma until 2014), Judith Greciet pursued development of the company by remoulding the strategy towards new growth-areas such as oncology.

Her mandate was renewed for 3 years at the annual shareholders’ general meeting of 2017.

Last updated on 02/03/2020

JUDITH GRECIET

DIRECTRICE GÉNÉRALE

Thomas HOFSTAETTER

Thomas Hofstaetter holds a PhD in Molecular Biology.

He carried out his international career, especially in Germany, the United States and Japan, within international pharmaceutical groups (Wyeth, Aventis, etc.) on strategic positions at the highest level in external growth and business development. Over the past two years, until December 2011, he headed VaxInnate Corporation and is now Board Member of Bionor ASA.

Thomas Hofstaetter has been a director of Onxeo since 31 May 2012. His mandate will expire at the shareholders’ annual general meeting of 2021.

Last updated on 08/12/2019

Thomas HOFSTAETTER

INDEPENDENT DIRECTOR

Nicolas TREBOUTA

Nicolas Trebouta is a Doctor of Medicine.

Co-founder of Chevrillon and Associates in 2000, Nicolas Trebouta has lead several buyouts within this structure including Picard frozen foods, CPI printing or Albingia insurance. Since 2004, he has been investing in biotechnology companies through his company Financière de la Montagne, either directly or through biotech funds. Nicolas Trebouta has been a shareholder of BioAlliance Pharma since 2008.

Financière de la Montagne has been a director since 29 June 2011. Their mandate will expire at the shareholders’ annual general meeting of 2020.

Last updated on 08/11/2019

Nicolas TREBOUTA

DIRECTOR - REPRESENTING FINANCIÈRE DE LA MONTAGNE

Jean-Pierre KINET

Prof. Jean-Pierre Kinet, M.D., is one of the most prominent immunology experts worldwide, most famous for discovering some of the genes and proteins constituting the immunoglobulin E receptor. These scientific breakthroughs contributed to the introduction of new diagnostic tools and therapies for diseases related to immune system dysregulation. He also is the co-founder and founder of two biotech companies (AB Science and Astarix), and is a board member of several other biotech companies in Europe.

He is Professor of Pathology at Harvard Medical School (Boston – USA). He is also a member of National Institute of Health (NIH) expert panels, and of the medical Board of the American Asthma Foundation in the USA. Jean-Pierre Kinet is a member of the Scientific Advisory Board of UCB Pharma and Managing Partner of iXLife Capital. Jean-Pierre Kinet received his medical degree from the University of Liege (Belgium), and was trained in internal medicine at the Liège University hospital. He has written over 200 publications and holds 10 American and global patents. In 1997, he received the NIH “Inventor Award” and in 2004 the prestigious “NIH Merit Award”. He was decorated in 2000 as a Knight of the National Order of Merit of the French Republic.

M. Jean-Pierre Kinet has been a director since April 6, 2016. His mandate will expire at the annual shareholders’ general meeting of 2022.

Last updated on 08/12/2019

Jean-Pierre KINET

INDEPENDENT DIRECTOR

Jean-Pierre BIZZARI

Jean-Pierre Bizzari, M.D., served as Executive Vice-President, Group Head, and Clinical Oncology Development (U.S., Europe, and Asia/Japan) at Celgene from 2008 to 2015. He has been involved in the clinical development of several anticancer agents such as Taxotere®, Eloxatin®, Abraxane®, Irinotecan® (CPT-11). As a world-renowned oncology expert, he is a member of the Scientific Advisory Board of the French National Cancer Institute (INCa) and European Organization of Research and Treatment of Cancer (EORTC) and Chairman of the New Drug Advisory Committee. Mr. Bizzari is also an active board member in various biotech companies, such as Transgene in France, Halozyme Therapeutics and Celator Pharmaceuticals in the US. He has published more than 70 articles in peer-reviewed journals and more than 160 abstracts in scientific congresses.

Bizzari joined the pharmaceutical industry in 1983 as Head of Oncology at the Institut de Recherches Internationales SERVIER (France). He then joined Rhône-Poulenc Rorer in 1993 as Vice President of Clinical Oncology, based in Paris and moved to Collegeville (PA – USA) in 1997. From 2002 until 2008, Mr. Bizzari served as Vice President of Clinical Oncology Development at Sanofi-Aventis in Malvern, PA before joining Celgene.

Jean-Pierre Bizzari holds a medical degree specialized in oncology from the University of Nice (France) and has trained successively at the Pitié-Salpêtrière hospital in Paris, at Ontario Cancer Institute, and Montreal Mac Gill Cancer Center in Canada.

M. Jean-Pierre Bizzari has been appointed director on April 6, 2016. His mandate will expire at the shareholders’ annual general meeting of 2019.

Last updated on 09/18/2019

Jean-Pierre BIZZARI

INDEPENDENT DIRECTOR

Elvira SANZ

Elvira Sanz is a Doctor in Pharmacy by the Complutense University of Madrid, with Extraordinary Prize of End of Career and graduated with an International MBA by the Business School ESDEN, first in her class. She has undertaken postgraduate courses in prestigious universities and international business schools, such as the Harvard Business School and Wharton University.

She has extensive experience in the pharmaceutical industry which she has accumulated over 25 years, starting as Research Scientist and occupying positions of growing responsibility across different business areas for MSD, Roche and Cyanamid.

In 1994, she joined Wyeth Farma as Director of Registrations and New Products. She was appointed in 1996 as Marketing Director and subsequently, in 1998, Deputy Director General until 2000, when she was appointed as Director General for Spain. In 2005, she joined Wyeth’s US headquarters to develop a global project, reporting to the CEO of the company, for the restructuration of Wyeth’s affiliates at global level. In 2007, she returned to Spain as General Director for Spain and Portugal. Following the acquisition of Wyeth by Pfizer in October 2009, she was named President and Director General, a position she held until 2015.

Elvira Sanz has been a member of the Board of Directors of the American Business Council and of the American Chamber of Commerce, and has been the President of LAWG (Laboratories Accreditation Working Group) in the period 2010-2012. From 2010 to 2014, she was Vice-President and then President of Farmaindustria, the Spanish pharmaceutical industry association.

Last updated on 09/18/2019

Elvira SANZ

INDEPENDENT DIRECTOR

Christine GARNIER

Christine Garnier is co-founder of the firm AEC Partners and is Managing Partner since 1998. She graduated from ESCP Europe in 1984. Her consultant activity is specialized in corporate, international and operational strategies, evolutions in business models and organizations, and the optimization of performance across the life science industry. During the last twenty years, Christine Garnier has managed more than 200 assignments on primary and specialty care products, vaccine products, as well as medical device and OTC. She accompanies executive committees and operational and functional management in the development of vision, their strategies and the evolution of their organizations. The perimeters of her interventions concentrate on Europe and fast developing countries (South East Asia, Latin America…) as well as international and corporate headquarters. She provides her clients with a strong expertise in strategy and organization coupled by her skill to identify and initiate necessary transformations. Before joining AEC Partners, Christine Garnier previously worked for 12 years in the pharmaceutical industry holding marketing positions in Wyeth and international marketing and strategic planning at Rhone Poulenc Rorer.

Last updated on 08/11/2019

Christine GARNIER

INDEPENDENT DIRECTOR

COMPANY

Profile
Executive Committee
Board of Directors
Join Us
Contact Us

Last updated on 09/14/2019